GlassScriptPhysician profile
Kathryn A Garner
NPI 1841280567
$3,356.29
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $59.57 · 2021: $821 · 2022: $917 · 2023: $780 · 2024: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,386.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $761.61 | 2019-2024 | |
| Astellas Pharma US INC | $256.80 | 2021-2024 | Veozah, Myrbetriq |
| Coopersurgical, INC. | $220.96 | 2019-2024 | Paragard T 380a |
| Exeltis, USA INC. | $206.48 | 2020-2024 | Slynd |
| Sumitomo Pharma America, INC. | $174.77 | 2023-2024 | Myfembree, Gemtesa |
| Axonics, INC. | $172.71 | 2021-2024 | Axonics, Bulkamid |
| Pfizer INC. | $165.34 | 2021-2023 | |
| Amgen INC. | $163.50 | 2021-2022 | |
| Medtronic, INC. | $151.33 | 2021-2024 | Interstim |
| Aspira Women'S Health INC | $106.33 | 2021-2023 | Ova1 |
| Myovant Sciences INC. | $105.50 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $101.12 | 2021-2024 | |
| Hologic Sales and Service, LLC | $89.02 | 2019-2023 | Acessa Provu System, Coolseal Generator, Myosure Tissue Removal Device |
| Organon LLC | $73.52 | 2021-2023 | Nexplanon |
| Biogen, INC. | $62.68 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $57.87 | 2021-2022 | |
| Avion Pharmaceuticals | $53.91 | 2021-2022 | |
| Ethicon US, LLC | $50.97 | 2022-2023 | Enseal, Stratafix, Dermabond Prineo |
| Evofem Biosciences, INC. | $47.08 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $41.97 | 2022 | |
| Merck Sharp & Dohme LLC | $31.96 | 2019 | |
| Shield Therapeutics INC | $29.60 | 2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $29.36 | 2021 | |
| Sanofi Pasteur INC. | $29.10 | 2024 | |
| Boston Scientific Corporation | $27.93 | 2022 | |
| Baxter Healthcare | $26.18 | 2024 | Perclot |
| Minerva Surgical, INC | $25.80 | 2019-2023 | |
| Roche Diagnostics Corporation | $19.84 | 2019 | |
| Channel Medsystems, INC. | $19.48 | 2023 | |
| Mycovia Pharmaceuticals, INC. | $19.00 | 2023 | Vivjoa |
| Gynesonics, INC. | $18.64 | 2022 | |
| Urovant Sciences INC | $15.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.